Health Care·Pharmaceuticals·$6.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | -$0.56 | N/A | +15.79% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | -$0.56 | N/A | +15.79% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about future developments. They are focused on advancing their clinical programs despite current challenges.
Management highlighted ongoing efforts to advance their pipeline.
They emphasized the importance of upcoming clinical trials.
There was a focus on maintaining operational efficiency.
Terns Pharmaceutical's earnings report showed a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue information and guidance may leave investors uncertain about the company's near-term prospects. However, management's focus on pipeline advancements suggests they are working towards future growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Feb 28, 2022